Galapagos plans to hand over Jyseleca and 400 employees to Alfasigma, reduce workforce by 100
Galapagos has a plan to hand over its Jyseleca business — its only commercial product — to Alfasigma, as well as lay off some of its own employees and transfer others to the Italian pharma.
In the potential deal, Galapagos will get €50 million ($53.3 million) upfront, potential milestone payments totaling €120 million ($127.9 million) and mid-single to mid-double-digit royalties on European sales for Alfasigma. About 400 jobs in 14 different European countries will also be transferred to Alfasigma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.